Diabetes Consultations™: Beyond Insulin: The Role of SGLT-2 Inhibitors in Care of Patients with T1DM
July 31, 2019
July 31, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc and Lilly USA, LLC.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses — maximum of 1.0 contact hours
All other health care professionals completing this course will be issued a statement of participation.
This activity is intended for community endocrinologists, diabetologists, primary care clinicians, nurse practitioners, physician assistants, certified diabetes educators, and nurses involved in the treatment and management of patients with type 1 diabetes (T1D). This activity will provide education to a broad multidisciplinary team who will be invited to participate.
Type 1 diabetes (T1D) has an extensive global presence and affects over 1.25 million Americans who live with the daily challenges of appropriate insulin dosing and glucose monitoring. Less than one-third of patients properly manage their diabetes and blood glucose levels and nearly half are either obese or overweight. However, escalating insulin doses carries many risks, including hypoglycemia and weight gain. Newer classes of antihyperglycemic agents used in type 2 diabetes offer a potential clinical option to effectively reach glycemic targets in patients with T1D. However, knowledge and competency among clinicians on risks and benefits, patient selection, and education on the use of SGLT-2 inhibitors as adjunctive therapy are crucial for effective clinical decision making and improving patient outcomes. Perspectives from an endocrinologist involved in clinical trials of these agents and a primary care physician with a diabetes center in their practice will offer learners well-rounded perspectives on best practices for optimizing treatment plans for patients with T1D.
Benefits of Participating
- Review current gaps in care of patients with T1D
- Understand the importance of appropriate patient selection and essential monitoring requirements for adjunctive treatment with an SLGT-2 inhibitor
- Learn new evidence-based strategies for hyperglycemic management of patients with T1D to maintain glycemic goals
Upon completion of this activity, participants should be able to:
- Identify patients with T1D who are not achieving their glycemic goals and who could benefit from adjunctive therapy to insulin
- Examine new and emerging data on SGLT1/2 inhibitors for potential adjunctive therapy for T1D
- Analyze risks and benefits associated with SLGT-2 inhibitor use in T1D
- Incorporate shared decision making to individualize therapy and improve patient outcomes in T1D
Paul P. Doghramji, MD, FAAFP
Collegeville Family Practice
Medical Director of Health Services
Paresh Dandona, MBBS, DPhil, FRCP, FACP, FACC
SUNY Distinguished Professor of Medicine, University at Buffalo
Chief, Division of Endocrinology, Diabetes and Metabolism
Center of Western New York
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Disclosures of Conflicts of Interest
Paul P. Doghramji, MD, FAAFP, has no relevant financial information of commercial interests to disclose.
Paresh Dandona, MBBS, DPhil, FRCP, FACP, FACC, has no relevant financial information of commercial interests to disclose.
The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
Method of Participation
Instructions for This Activity and Receiving Credit
- You will need to log in to participate in the activity.
- Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
- At the end of the activity, educational content/audio files will be available for your reference.
- In order to receive a CME/CE certificate, you must complete the activity.
- Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure of Unlabeled Use
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.